Why Menopause Treatment Guidelines Matter
The menopause treatment guidelines published by major medical organizations shape what your doctor prescribes, what your insurance covers, and what the standard of care looks like in your country. Three organizations dominate the landscape: the American College of Obstetricians and Gynecologists (ACOG), the North American Menopause Society (NAMS, now renamed The Menopause Society), and the National Institute for Health and Care Excellence (NICE) in the UK. Each has its own approach, its own evidence thresholds, and its own blind spots. Understanding where they agree and where they diverge helps you make better treatment decisions.
The menopause treatment overview on this site covers the full range of available options, but this article is about the clinical rulebooks that doctors use. Knowing what the guidelines say — and what they do not say — puts you in a stronger position in any treatment conversation. The differences between them matter, particularly for women with complex medical histories.
NAMS 2022 Hormone Therapy Position Statement
NAMS published its most recent hormone therapy position statement in July 2022, replacing the 2017 version. It is the most clinically detailed and practically useful of the three major guidelines. The central recommendation is unambiguous: hormone therapy is the most effective treatment for vasomotor symptoms and should be offered to symptomatic women under 60 or within 10 years of menopause onset, without unnecessary restrictions. The statement explicitly rejects the “fear-based” approach that followed the 2002 WHI publication.
The NAMS guideline is the only one that provides specific estrogen dose ranges for different delivery methods. For transdermal estradiol, it recommends starting doses of 0.025 to 0.0375 mg/day for patches, with titration up to 0.1 mg/day based on symptom response. For oral estradiol, it recommends 0.5 to 1 mg/day. For conjugated equine estrogens, 0.3 to 0.45 mg/day. These specifics matter because many women are started on unnecessarily high doses that increase side effect risk without better symptom control.
NAMS also takes the strongest position on bioidentical hormones. The statement says compounded bioidentical hormones “are not recommended” because of lack of FDA approval, batch-to-batch variability (potency ranging from 70% to 130% of labeled dose according to a 2022 FDA analysis), and absence of long-term safety data. This puts NAMS at odds with a vocal patient community that prefers compounded products, but the position is consistent with the evidence. The bioidentical hormones article on this site covers the controversy in detail.
ACOG Practice Bulletin on Menopausal Symptoms
ACOG’s main practice bulletin on menopausal symptoms was published in January 2014 and has not been fully updated since — a gap that has drawn criticism from menopause specialists. The recommendation framework is more conservative than NAMS. ACOG recommends that hormone therapy be used “at the lowest dose and for the shortest duration needed” to control symptoms, a phrasing that some experts argue reflects the lingering caution from the 2002 WHI.
The ACOG 2024 updated position on genitourinary syndrome of menopause is more current and more useful. It recommends low-dose vaginal estrogen as first-line treatment for moderate to severe GSM symptoms and notes that there is “no justification for a mandatory treatment duration limit” — a significant shift from earlier guidance. ACOG also explicitly states that vaginal estrogen can be used in breast cancer survivors, in consultation with the woman’s oncologist. This is important because many breast cancer survivors are told they cannot use any form of estrogen, when the evidence shows minimal systemic absorption from vaginal products.
The ACOG guideline is the least prescriptive of the three on specific doses and regimens. It does not specify starting doses for different HRT formulations and does not include a treatment algorithm. This gives clinicians more flexibility but also less guidance — and in practice, it means many ACOG members are not following evidence-based prescribing. A 2024 survey in Menopause found that only 34% of ob-gyns felt confident prescribing hormone therapy, and 58% said the ACOG guideline was not detailed enough to guide their practice. The HRT options guide fills in the practical prescribing details that ACOG leaves out.
NICE Guideline NG23: The UK Standard (Updated 2024)
The NICE guideline on menopause is the most recently updated of the three major menopause treatment guidelines. The original NG23 was published in November 2015, and the comprehensive update came in November 2024. The update was substantial: NICE added 19 new recommendations and modified 12 existing ones. The result is the most current, evidence-based menopause treatment framework available anywhere.
The most important change in the 2024 NICE update is the removal of arbitrary HRT duration limits. The previous guideline said HRT should be “reviewed annually” but implied a 5-year limit based on the WHI data. The 2024 guideline explicitly states that “the decision to continue hormone therapy should be based on an annual discussion of benefits and risks, with no predetermined maximum duration.” This aligns with NAMS and represents a definitive break from the post-WHI caution.
NICE 2024 also added cognitive behavioral therapy as a formal treatment option for vasomotor symptoms — the first major guideline to do so. The recommendation was based on the MENOS 2 trial (2025) and 18 other RCTs showing CBT’s effectiveness for hot flash bother. The guideline also updated the approach to genitourinary symptoms: vaginal estrogen is now recommended first-line for GSM, with the note that women can self-administer with remote follow-up after initial prescription.
The NICE guideline has one limitation: it is written for the UK National Health Service, so treatment availability and cost-effectiveness are factored into recommendations. Some treatments recommended by NAMS — like Veozah — are not yet NICE-recommended because of cost concerns. Veozah was recommended by NICE in draft guidance published June 2024 but final guidance was still pending at the time of the November 2024 update. The non-hormonal treatment guide covers the full range of options available in both the US and UK.
Where the Guidelines Agree
Despite their differences in tone and level of detail, the three major menopause treatment guidelines agree on several core points. First, hormone therapy is the most effective treatment for vasomotor symptoms — all three organizations rate it as first-line. Second, the risks of hormone therapy — breast cancer, venous thromboembolism, stroke — are low for women under 60 or within 10 years of menopause onset. Third, the route of administration matters: transdermal estrogen carries lower clotting risk than oral and should be preferred for women with obesity, hypertension, or migraine with aura.
All three guidelines also agree that treatment should be individualized. There is no one-size-fits-all menopause treatment, and the guidelines all emphasize shared decision-making. The NAMS 2022 statement puts it most directly: “Hormone therapy decisions should be based on a woman’s individual risk profile, symptom severity, and preferences, not on arbitrary age or duration limits.” ACOG’s 2014 bulletin and NICE’s 2024 update make essentially the same point, though with less forceful language.
The third area of agreement is that genitourinary syndrome of menopause is underdiagnosed and undertreated. NAMS (2020 GSM position statement), ACOG (2024 update), and NICE (2024 update) all recommend that clinicians proactively ask about vaginal symptoms rather than waiting for women to raise them. The 2024 ACOG position is particularly notable because it removes the previous caution about vaginal estrogen requiring progestogen — it does not, and the statement now makes that clear.
Where They Differ
The most significant difference between the guidelines is the timeline of their origin. ACOG’s main guideline is from 2014 — 12 years old as of 2026. NAMS 2022 is moderately current. NICE 2024 is the most up-to-date. This timeline matters because menopause research has moved fast in the last decade. The 2024 NICE guideline incorporated data from the KEEPS Continuation Study, the ELITE follow-up, and the MsFLASH network — studies that ACOG’s 2014 guideline predates entirely.
The second major difference is how they handle non-hormonal treatments. NAMS published a standalone non-hormonal management position statement in 2023 that covers Veozah, SSRIs/SNRIs, gabapentin, and CBT in detail. NICE 2024 added CBT but has not fully evaluated Veozah. ACOG’s 2014 bulletin mentions SSRIs and gabapentin but not Veozah, which did not exist at the time. Women in the US have more non-hormonal options covered by insurance than women in the UK, where NICE cost-effectiveness thresholds limit access to newer drugs.
The third difference is the role of testosterone. NAMS 2022 says testosterone therapy may be considered for postmenopausal women with hypoactive sexual desire disorder, though no FDA-approved testosterone product exists for women in the US. NICE 2024 says the same but notes that testosterone is not licensed for women in the UK and must be prescribed off-label. ACOG’s 2014 guideline does not address testosterone at all. The testosterone therapy guide explains the off-label landscape in more detail.
How to Use the Guidelines in Your Own Care
Understanding menopause treatment guidelines empowers you to have better conversations with your doctor. If your doctor says “HRT is only safe for five years,” they are following outdated guidance — the 2024 NICE and 2022 NAMS guidelines both reject that limit. If your doctor says “your symptoms aren’t bad enough for treatment,” the NICE 2024 guideline explicitly states that symptom severity should be assessed by the patient, not the clinician. If your doctor prescribes an oral HRT but you have high blood pressure, ask about transdermal options — all three guidelines agree that patches are safer for women with cardiovascular risk factors.
The guidelines are not laws, and individual clinicians may have valid reasons for different approaches. But the guidelines set the standard of care, and treatment that falls significantly outside the guidelines should be questioned. The hormone replacement therapy guide on this site includes a printable checklist of guideline-based questions to bring to your next appointment. The complete treatment options guide translates each guideline recommendation into actionable steps.